Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

Investigators report that estradiol works as well as luteinizing hormone–releasing hormone agonists for testosterone suppression and have a much better side-effect profile.

Transdermal estradiol patches may be an alternative to LHRHas when combined with ARPIs to treat mHSPC, researchers say.

A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate ...

Melbourne-based scientists have, for the first time, discovered how to "switch off" a molecule which is one of the top ...

A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate cancer progression to help identify its clinical outcomes.

Senior doctors responsible for monitoring cancer care in England and Wales are concerned failings in NHS services are ...

Providence Alaska Medical Center will be the first in the state to offer Pluvicto, an innovative therapy for metastatic ...

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Glenn Bauman discussing a prospective provincial registry of PSMA PET/CT for recurrent prostate cancer. While most ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

A major discovery by Australian researchers of a key driver of prostate cancer could lead to the next generation of targeted ...